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CASE LETTER

Exuberant Lymphomatoid Papulosis
of the Head and Upper Trunk
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regression is crucial for distinguishing LyP from other
forms of cutaneous lymphoma.2 The disease course is
variable, lasting anywhere from a few months to decades.
Histopathologically, LyP consists of a frequently CD30+
lymphocytic proliferation in multiple described patterns.1
We report a case of LyP in a patient who initially presented with pink edematous papules and vesicles that
progressed to crusted ulcerations, nodules, and deep
necrotic eschars on the scalp, neck, and upper trunk.
Multiple biopsies and T-cell gene rearrangement studies
were necessary to make the diagnosis.
A 73-year-old man presented with edematous crusted
papules and nodules as well as scarring with serous
drainage on the scalp and upper trunk of several months’
duration. He also reported pain and pruritus. He had
a medical history of B-cell CD20− chronic lymphocytic
leukemia (CLL) that was treated with fludarabine, cyclophosphamide, rituximab, and intravenous immunoglobulin approximately one year prior and currently was in
remission; prostate cancer treated with prostatectomy;
hypertension; and type 2 diabetes mellitus. His medications included metoprolol, valsartan, and glipizide.
Histopathology revealed a hypersensitivity reaction,
and the clinicopathologic correlation was believed to
represent an exuberant arthropod bite reaction in the
setting of CLL. The eruption responded well to oral prednisone and topical corticosteroids but recurred when the
medications were withdrawn. A repeat biopsy resulted
in a diagnosis of atypical eosinophil-predominant Sweet
syndrome. The condition resolved.
Three years later he developed multiple honey-crusted,
superficial ulcers as well as serous, fluid-filled vesiculobullae on the head. A tissue culture revealed Proteus
mirabilis, Staphylococcus aureus, and Enterococcus faecalis,
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 ymphomatoid papulosis (LyP) is a chronic, recurL
ring, self-healing, primary cutaneous lymphoproliferative disorder characterized by red-brown papules
or nodules, some with hemorrhagic crust or central
necrosis, often occurring in crops and in various
stages of evolution.
Histopathologically, LyP consists of a frequently
CD30+ lymphocytic proliferation in multiple
described patterns.
Lymphomatoid papulosis is an indolent cutaneous
lymphoma; however, it is associated with the potential
development of a second hematologic malignancy.
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To the Editor:
Lymphomatoid papulosis (LyP) is a chronic, recurring,
self-healing, primary cutaneous lymphoproliferative disorder. This disease affects patients of all ages but most
commonly presents in the fifth decade with a slight male
predominance.1 The estimated worldwide incidence is
1.2 to 1.9 cases per 1,000,000 individuals, and the 10-year
survival rate is close to 100%.1 Clinically, LyP presents as
a few to more than 100 red-brown papules or nodules,
some with hemorrhagic crust or central necrosis, often
occurring in crops and in various stages of evolution.
They most commonly are distributed on the trunk and
extremities; however, the face, scalp, and oral mucosa
rarely may be involved. Each lesion may last on average
3 to 8 weeks, with residual hyperpigmentation or
hypopigmentation of the skin or superficial varioliform scars. The clinical characteristic of spontaneous
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oral minocycline 100 mg twice daily, topical clobetasol,
and topical mupirocin.
Lymphomatoid papulosis is an indolent cutaneous
lymphoma; however, it is associated with the potential
development of a second hematologic malignancy, with
some disagreement in the literature concerning the exact
percentage.3 In some studies, lymphoma has been estimated to occur in less than 20% of cases.4,5 Wieser et al1
reported a retrospective analysis of 180 patients with LyP
that revealed a secondary malignancy in 52% of patients.
They also reported that the number of lesions and the
symptom severity were not associated with lymphoma
development.1 Similarly, Cordel et al6 reported a diagnosis of lymphoma in 41% of 106 patients. These analyses
reveal that the association with lymphoma may be higher
than previously thought, but referral bias may be a confounding factor in these numbers.1,5,6 Associated malignancies may occur prior to, concomitantly, or years after
the diagnosis of LyP. The most frequently reported malignancies include mycosis fungoides, Hodgkin lymphoma,
and primary cutaneous anaplastic large cell lymphoma.1,4
Nicolaou et al3 indicated that head involvement was
more likely associated with lymphoma. Our patient
had a history of CLL prior to the development of LyP,
and it continues to be in remission. The incidence of
CLL in patients with LyP is reported to be 0.8%.4 Our
patient had an exuberant case of LyP predominantly
involving the head, neck, and upper torso, which is an
unusual distribution. Vesiculobullous lesions also are
uncharacteristic of LyP and may have represented concomitant bullous impetigo, but bullous variants of LyP
also have been reported.7 Due to the unique distribution
and characteristic scarring, Brunsting-Perry cicatricial
pemphigoid also was considered in the clinical differential diagnosis.
The pathogenesis of LyP associated with malignancy
is not definitively known. Theories propose that progression to a malignant clonal T-cell population may come
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and was negative for acid-fast bacteria and fungus. Biopsy
of these lesions revealed dermal ulceration with a mixed
inflammatory infiltrate and numerous eosinophils as
well as a few clustered CD30+ cells; direct immunofluorescence was negative. An extensive laboratory workup
including bullous pemphigoid antigens, C-reactive protein, antinuclear antibodies comprehensive profile, antineutrophil cytoplasmic antibodies, rheumatoid factor,
anticyclic citrullinated peptide antibodies, serum protein
electrophoresis, lactate dehydrogenase, complete blood
cell count with differential, complete metabolic profile,
thyroid-stimulating hormone, uric acid, C3, C4, immunoglobulin profile, angiotensin-converting enzyme level,
and urinalysis was unremarkable. He improved with
courses of minocycline, prednisone, and topical clobetasol, but he had periodic and progressive flares over
several months with punched-out crusted ulcerations
developing on the scalp (Figure 1A) and neck (Figure 1B).
The oral and ocular mucosae were uninvolved, but the
nasal mucosa had some involvement.
A repeat biopsy demonstrated an atypical CD30+ lymphoid infiltrate favoring LyP. T-cell clonality performed on
this specimen and the prior biopsy demonstrated identical T-cell receptor β and γ clones. CD3, CD5, CD7, and
CD4 immunostains highlighted the perivascular, perifollicular, and folliculotropic lymphocytic infiltrate. CD8
highlighted occasional background small T cells with only
a few folliculotropic forms. A CD30 study revealed several
scattered enlarged lymphocytes, and CD20 displayed a
few dispersed B cells. A repeat perilesional direct immunofluorescence study was again negative. With treatment,
he later formed multiple dry punched-out ulcers with
dark eschars on the scalp, posterior neck, and upper back.
There were multiple scars on the head, chest, and back,
and no vesicles or bullae were present (Figure 2). The
patient was presented at a meeting of the Philadelphia
Dermatological Society and a consensus diagnosis of LyP
was reached. The patient has continued to improve with
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FIGURE 1. Lymphomatoid papulosis.
A, The patient’s scalp demonstrated
punched-out crusted ulcerations.
B, Multiple pink edematous papules
and crusted ulcerations were noted
on the neck.
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in their retrospective analysis of 180 patients. The number of lesions, frequency of outbreaks, and extent of
the scarring can dictate the treatment approach for
LyP. Conservative topical therapies include corticosteroids, bexarotene, and imiquimod. Mupirocin may help
to prevent infection of ulcerated lesions.1,2 Low-dose
methotrexate has been shown to be the most efficacious
treatment in reducing the number of lesions, particularly
for scarring or cosmetically sensitive areas. Oral methotrexate at a dosage of 10 mg to 25 mg weekly tapered
to the lowest effective dose may suppress outbreaks of
LyP lesions.1,2 Other therapies include psoralen plus
UVA, UVB, interferon alfa-2a, oral bexarotene, oral acyclovir or valacyclovir, etretinate, mycophenolic acid,
photodynamic therapy, oral antibiotics, excision, and
radiotherapy.1,2 Systemic chemotherapy and total-skin
electron beam therapy have shown efficacy in clearing
the lesions; however, the disease recurs after discontinuation of therapy.2 Systemic chemotherapy is not recommended for the treatment of LyP, as risks outweigh the
benefits and it does not reduce the risk for developing
lymphoma.1 The prognosis generally is good, though
long-term follow-up is imperative to monitor for the
development of other lymphomas.
Our patient presented with LyP a few months after
completing chemotherapy for his CLL. It is unknown if
he developed LyP just before the time of presentation,
or if he may have developed it at the same time as his
CLL by a common inciting event. In the latter case, it
is speculative that the LyP may have been controlled
by chemotherapy for his CLL, only to become clinically
apparent after discontinuation, then naturally remit for
a longer period. Case reports such as ours with unusual
clinical presentations, B-cell lymphoma associations, and
unique timing of lymphoma onset may help to provide
insight into the pathogenesis of this disease.
We highlighted an unusual case of LyP that presented
clinically with crusted ulcerations as well as vesiculobullous and edematous papules that progressed into deep
punched-out ulcers with eschars, nodules, and scarring
on the head and upper trunk. Lymphomatoid papulosis
can be difficult to diagnose histopathologically at the
early stages, and multiple repeat biopsies may be necessary to confirm the diagnosis. T-cell gene rearrangement
and immunohistochemistry studies are helpful along
with clinical correlation to establish a diagnosis in these
cases. We recommend that physicians keep LyP on the
differential diagnosis for patients with similar clinical
presentations and remain vigilant in monitoring for the
development of secondary lymphoma.
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FIGURE 2. Lymphomatoid papulosis. A, Multiple dry, punched-out
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ulcers with dark eschars and scarring later formed on the scalp with
treatment. B, Crusted ulcerations and scarring on the upper back.

from cytogenetic events, inadequate host response, or
persistent antigenic or viral stimulation.4 Studies have
demonstrated overlapping T-cell receptor gene rearrangement clones in lesions in patients with both LyP
and mycosis fungoides, suggesting a common origin
between the diseases.8 Other theories suggest that LyP
may arise from an early, reactive, polyclonal lymphoid
expansion that evolves into a clonal neoplastic process.4 Interestingly, LyP is a clonal T-cell disorder, while
Hodgkin lymphoma and CLL are B-cell disorders. Thus,
reports of CLL occurring with LyP, as in our patient, may
support the theory that LyP arises from an early stem-cell
or precursor-cell defect.4
There is no cure for LyP and data regarding the
potential of aggressive therapy on the prevention of secondary lymphomas is lacking. Wieser et al1 reported that
treatment did not prevent the progression to lymphoma
E14 I CUTIS®
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